Atripla

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.

Gilead gets EU nod for TAF-based triple therapy for HIV

Atripla in 20016. ... Since then, Atripla has grown into a $3bn-plus product. "People living with HIV today are increasingly likely to be receiving treatment for other conditions - such as heart and liver disease -

ViiV and Janssen take long-acting HIV regimen into phase III

Gilead currently dominates the HIV treatment sector thanks to drugs like Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (favirenz/emtricitabine/tenofovir disoproxil fumarate), but ViiV is fighting back.

ViiV agrees $1.5bn deal to acquire BMS' HIV assets

cobicistat), Sustiva (efavirenz) and big-selling Atripla (efavirenz, emtricitabine, and tenofovir).

ViiV boosted by positive phase III results for HIV drug Triumeq

The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.

BMS' HIV combination Evotaz cleared in Europe

s Atripla and Stribild, Johnson &Johnson's Complera and ViiV Healthcare's Triumeq.

1 2 3 4 5 6 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Account Manager- Healthcare Advertising: Negotiable

Editorial Manager - MedComms: DOE

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director: Competitive Salary Offered

Systematic Reviewer - Oxford: Negotiable

Business Director: Competitive Salary Offered

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Editorial Assistant – Greater Manchester: DOE

Business Development Director – Health Education: excellent commission

Account Manager / Account Director: Competative

Associate Director: £75, 000-90, 000

Medical (Scientific) Director: £120, 000 benefits

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Healthcare Communications Account Directors x 2: Salary TBC

Account Executive/ Senior Account Executive: competitive Salary Offfered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Experienced Medical Writers: Competitive Salary and Benefits

Associate Medical Director: Excellent PTO, bonus and 401k package

Senior Account Manager: Competitive Salary Offered

Account Director – Healthcare Marketing – Berks: Salary TBC

Principal Health Economist - North-West: Negotiable

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...